221 related articles for article (PubMed ID: 16607930)
1. Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Bayram F; Tanriverdi F; Kurtoğlu S; Atabek ME; Kula M; Kaynar L; Keleştimur F
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):275-9. PubMed ID: 16607930
[TBL] [Abstract][Full Text] [Related]
2. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation.
Barros ER; Dias da Silva MR; Kunii IS; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2008 Aug; 21(8):811-8. PubMed ID: 18825883
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
4. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
5. Fractures on bisphosphonates in osteoporosis pseudoglioma syndrome (OPPG): pQCT shows poor bone density and structure.
Streeten EA; Ramirez S; Eliades M; Jaimungal S; Chandrasekaran S; Kathleen R; Holmes Morton D; Puffenberger EG; Herskovitz R; Leonard MB
Bone; 2015 Aug; 77():17-23. PubMed ID: 25892485
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis-pseudoglioma syndrome: clinical, genetic, and treatment-response study of 10 new cases in Greece.
Papadopoulos I; Bountouvi E; Attilakos A; Gole E; Dinopoulos A; Peppa M; Nikolaidou P; Papadopoulou A
Eur J Pediatr; 2019 Mar; 178(3):323-329. PubMed ID: 30499050
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
9. [Cyclic intravenous pamidronate in treatment of osteoporosis].
Vujasinović-Stupar N; Pilipović N; Branković S
Med Pregl; 2004; 57(11-12):545-50. PubMed ID: 16107000
[TBL] [Abstract][Full Text] [Related]
10. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
Salehpour S; Tavakkoli S
J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
[TBL] [Abstract][Full Text] [Related]
11. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
Brown JJ; Zacharin MR
J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates.
Streeten EA; McBride D; Puffenberger E; Hoffman ME; Pollin TI; Donnelly P; Sack P; Morton H
Bone; 2008 Sep; 43(3):584-90. PubMed ID: 18602879
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
Arantes HP; Barros ER; Kunii I; Bilezikian JP; Lazaretti-Castro M
J Bone Miner Res; 2011 Dec; 26(12):2823-6. PubMed ID: 21997141
[TBL] [Abstract][Full Text] [Related]
15. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Reeves HL; Francis RM; Manas DM; Hudson M; Day CP
Liver Transpl Surg; 1998 Sep; 4(5):404-9. PubMed ID: 9724478
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Celli M; D'Eufemia P; Persiani P; Turchetti A; Febbo A; D'Alfonso Y; Celli L; Zambrano A
Osteoporos Int; 2017 Nov; 28(11):3277-3280. PubMed ID: 28866852
[TBL] [Abstract][Full Text] [Related]
17. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
Plotkin H; Coughlin S; Kreikemeier R; Heldt K; Bruzoni M; Lerner G
Dev Med Child Neurol; 2006 Sep; 48(9):709-12. PubMed ID: 16904014
[TBL] [Abstract][Full Text] [Related]
18. Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens.
Martinez-Soto T; Pacaud D; Stephure D; Trussell R; Huang C
J Pediatr Endocrinol Metab; 2011; 24(5-6):271-4. PubMed ID: 21823522
[TBL] [Abstract][Full Text] [Related]
19. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
[TBL] [Abstract][Full Text] [Related]
20. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis.
Gandrud LM; Cheung JC; Daniels MW; Bachrach LK
J Pediatr Endocrinol Metab; 2003; 16(6):887-92. PubMed ID: 12948302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
